We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
(-9.8%)
Cap. Flow
-$772M
Cap. Flow
% of AUM
-28.57%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$39.7M |
| 2 |
Humana
HUM
|
+$32.6M |
| 3 |
MAZE
Maze Therapeutics
MAZE
|
+$29.9M |
| 4 |
Avalo Therapeutics
AVTX
|
+$25.8M |
| 5 |
ALMR
Alamar Biosciences
ALMR
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$78.9M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$71.8M |
| 3 |
CG Oncology
CGON
|
+$66.7M |
| 4 |
argenx
ARGX
|
+$55.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.44% |
| 2 | Miscellaneous | 3.68% |
| 3 | Financials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAI
1
Caris Life Sciences
CAI
$7.24B
| $147M | 5.44% |
8,256,032
+246,585
| +3% | +$4.41M |
|
|
HNGE
2
Hinge Health
HNGE
$7.05B
| $110M | 4.08% |
1,330,127
-124,996
| -9% | -$6.79M |
|
3
Glaukos
GKOS
$10.6B
| $82.7M | 3.06% |
591,927
-171,578
| -22% | -$21.7M |
|
4
Edgewise Therapeutics
EWTX
$4.64B
| $81.1M | 3% |
1,996,965
-350,618
| -15% | -$12.1M |
|
5
Spyre Therapeutics
SYRE
$7.97B
| $78.1M | 2.89% |
879,467
-53,356
| -6% | -$3.89M |
|
6
iRhythm Holdings
IRTC
$3.96B
| $77.8M | 2.88% |
654,262
+44,070
| +7% | +$5.12M |
|
7
NeoGenomics
NEO
$2.32B
| $71.8M | 2.65% |
4,918,202
-699,200
| -12% | -$6.75M |
|
8
Kodiak Sciences
KOD
$2.37B
| $69.6M | 2.58% |
1,787,318
-31,347
| -2% | -$1.22M |
|
9
Xenon Pharmaceuticals
XENE
$5.81B
| $68.3M | 2.53% |
1,131,452
-207,000
| -15% | -$11.5M |
|
10
Monte Rosa Therapeutics
GLUE
$1.14B
| $59.3M | 2.19% |
2,451,562
-755,012
| -24% | -$14.3M |
|
11
Dianthus Therapeutics
DNTH
$5.92B
| $58M | 2.14% |
594,562
-304,802
| -34% | -$26.6M |
|
|
12
Neurocrine Biosciences
NBIX
$15.7B
| $56.7M | 2.1% |
336,171
-315,950
| -48% | -$46.9M |
|
|
13
Alphatec Holdings
ATEC
$1.46B
| $56.5M | 2.09% |
6,531,439
+4,358,714
| +201% | +$39.7M |
|
|
GENB
14
Generate Biomedicines
GENB
$1.97B
| $55.4M | 2.05% |
3,283,844
-309,155
| -9% | -$4.21M |
|
15
Maravai LifeSciences
MRVI
$1.14B
| $54.3M | 2.01% |
8,702,921
-1,537,243
| -15% | -$6.64M |
|
16
Krystal Biotech
KRYS
$10.4B
| $47.9M | 1.77% |
128,975
-53,450
| -29% | -$16M |
|
|
17
Humana
HUM
$46.3B
| $45.5M | 1.68% |
+114,500
| New | +$32.6M |
|
18
Thermo Fisher Scientific
TMO
$230B
| $44.8M | 1.66% |
89,395
-3,520
| -4% | -$1.69M |
|
19
Kymera Therapeutics
KYMR
$9.82B
| $43.4M | 1.6% |
378,163
+40,604
| +12% | +$3.49M |
|
20
Rhythm Pharmaceuticals
RYTM
$7.38B
| $42.3M | 1.57% |
381,128
+70,500
| +23% | +$6.37M |
|
|
DMRA
21
Damora Therapeutics
DMRA
$1.79B
| $42.1M | 1.56% |
1,620,377
+725,531
| +81% | +$17.6M |
|
22
Acadia Pharmaceuticals
ACAD
$5.02B
| $41.7M | 1.54% |
1,646,399
-824,800
| -33% | -$18.1M |
|
23
BrightSpring Health Services
BTSG
$11.7B
| $41.6M | 1.54% |
596,753
-419,809
| -41% | -$23.3M |
|
24
Transmedics
TMDX
$3.07B
| $40.5M | 1.5% |
609,715
+280,324
| +85% | +$23.7M |
|
|
MBX
25
MBX Biosciences
MBX
$3.03B
| $39.2M | 1.45% |
710,880
-781,587
| -52% | -$27.3M |
|
Similar funds
CWM
M
AG
NIM
GC
BIAS
CCM
ACP
Braidwell's Q2 2026 Portfolio in Review
As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Humana worth $45.5M.
- Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
- Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
- Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
- Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
- Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
- Braidwell opened 24 new positions and closed 23 in Q2 2026.
- Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.
Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.